Does concomitant diazepam and ethanol use modulate age-related cognitive decline in mice?

Autor: Carton L; Univ. Lille, Inserm, CHU Lille Lille Neuroscience and Cognition, Degenerative and Vascular Cognitive Disorders, UMR-S1172, Pharmacology department, F-59000 Lille, France. Electronic address: louise.carton@univ-lille.fr., Landmann C; Univ. Lille, Inserm, CHU Lille Lille Neuroscience and Cognition, Degenerative and Vascular Cognitive Disorders, UMR-S1172, Pharmacology department, F-59000 Lille, France., Auger F; Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, US 41 - UMS 2014 - PLBS, In vivo imaging and function platform, F-59000 Lille, France., Durieux N; Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, US 41 - UMS 2014 - PLBS, In vivo imaging and function platform, F-59000 Lille, France., Laloux C; Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, US 41 - UMS 2014 - PLBS, In vivo imaging and function platform, F-59000 Lille, France., Kyheng M; Univ. Lille, CHU Lille, ULR 2694 - METRICS: évaluation des technologies de santé et des pratiques médicales, F-59000 Lille, France; CHU Lille, Département de Biostatistiques, F-59000 Lille, France., Petrault M; Univ. Lille, Inserm, CHU Lille Lille Neuroscience and Cognition, Degenerative and Vascular Cognitive Disorders, UMR-S1172, Pharmacology department, F-59000 Lille, France., Timmerman K; Univ. Lille, Inserm, CHU Lille Lille Neuroscience and Cognition, Degenerative and Vascular Cognitive Disorders, UMR-S1172, Pharmacology department, F-59000 Lille, France., Potey C; Univ. Lille, Inserm, CHU Lille Lille Neuroscience and Cognition, Degenerative and Vascular Cognitive Disorders, UMR-S1172, Pharmacology department, F-59000 Lille, France., Bergeron S; Univ. Lille, Inserm, CHU Lille Lille Neuroscience and Cognition, Degenerative and Vascular Cognitive Disorders, UMR-S1172, Pharmacology department, F-59000 Lille, France., Deguil J; Univ. Lille, Inserm, CHU Lille Lille Neuroscience and Cognition, Degenerative and Vascular Cognitive Disorders, UMR-S1172, Pharmacology department, F-59000 Lille, France., Bordet R; Univ. Lille, Inserm, CHU Lille Lille Neuroscience and Cognition, Degenerative and Vascular Cognitive Disorders, UMR-S1172, Pharmacology department, F-59000 Lille, France.
Jazyk: angličtina
Zdroj: Life sciences [Life Sci] 2024 Dec 15; Vol. 359, pp. 123216. Date of Electronic Publication: 2024 Nov 05.
DOI: 10.1016/j.lfs.2024.123216
Abstrakt: Background: Concomitant use of alcohol and benzodiazepines are described among elderly, raising concerns about their combined impact on memory. We aimed to evaluate the long-term impact of chronic diazepam use associated with ethanol intoxication on memory in aging mice.
Methods: Twelve-month-old male C57BL6 mice were assigned into 4 groups: ethanol (OH), diazepam (DIA), diazepam + ethanol (DOH) and control (CTL). For 16 weeks, ethanol was available ad libitum and diazepam was mixed with food. Behavioral testing, performed during and after treatment cessation included working memory and visual recognition memory assessment. The second session was implemented with spatial reference learning and memory assessment in the Barnes maze test. In vivo magnetic resonance spectroscopy (MRS) acquisitions were performed to quantify hippocampal metabolites during and after cessation treatment.
Results: During treatment, visual recognition memory was significantly different between groups with the DIA group exhibiting the worst performance. MRS acquisition highlighted higher glutamate and choline levels in OH and DOH groups in comparison to CTL and DIA groups. After treatment wash-out, there was no difference between in the different memories evaluated. Only the learning phase of the spatial reference memory test differed significantly with worst performance in OH groups. Three months after treatment cessation, there was no remanent effect of diazepam + ethanol on hippocampal metabolites changes.
Conclusions: We did not evidence additive effect of ethanol and diazepam on memory and hippocampal metabolite levels. The disturbances observed during treatment were no remanent, highlighting the benefits of discontinuing these substances.
Competing Interests: Declaration of competing interest The authors have no conflict of interest to disclose.
(Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: